Media Center

Recent News

06/15/20
Summary ToggleACADIA Pharmaceuticals Submits Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
06/02/20
Summary ToggleACADIA Pharmaceuticals to Present at the Goldman Sachs 41st Annual Global Healthcare Conference on June 9, 2020
05/28/20
Summary ToggleACADIA Pharmaceuticals Appoints Mark Schneyer as Senior Vice President, Business Development and Chief Business Officer
05/26/20
Summary ToggleACADIA Pharmaceuticals to Combine CLARITY-2 and CLARITY-3 Phase 3 Studies Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder
05/21/20
Summary ToggleACADIA Pharmaceuticals to Present Pimavanserin Clinical Data at the 2020 American Society of Clinical Psychopharmacology Virtual Annual Meeting
2019 | 2018 | 2017 | Archive
icon-information1

COVID-19 Pandemic Information

ACADIA COVID-19 Pandemic Response

SCIENTIFIC

Media Statements

ACADIA Pharmaceuticals Responds to False and Misleading Claims About NUPLAZID